UP!

MACK $14.77

MACK target price
14.77
0
0
Merrimack Pharmaceuticals
Industry Pharmaceuticals
Founded 2000 in Cambridge, Massachusetts
Headquarters Cambridge, Massachusetts, United States
Number of employees
426 (2016)
Website www.merrimack.com

Merrimack Pharmaceuticals is a pharmaceutical company based in Cambridge, Massachusetts, United States. They specialize in developing drugs for the treatment of cancer.

Merrimack first FDA-approved drug was approved in 2015; Onivyde, a liposome encapsulated version of irinotecan is used for treating pancreatic adenocarcinoma. It was approved for use in Europe the following year.

Merrimack was founded by a group of scientists from MIT and Harvard University in 2000.

In 2016, Merrimack had 426 full-time employees, 103 of which had an MD or PhD.

In October 2016, CEO Robert Mulroy resigned and the company announced they would be laying off 20% of its employees. In January 2017, interim CEO Gary Crocker resigned and the board of directors appointed Richard Peters to be president and CEO. Peters previously worked at Sanofi and was a faculty member at Harvard University.

In January 2017, French pharmaceutical company Ipsen announced they would be purchasing Onivyde from Merrimack for approximately $1 billion.

Merrimack has four drugs in clinical development.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2016-05-26 Initiated Coverage Robert W. Baird Neutral $8.00
2016-05-20 Reiterated Rating Brean Capital Buy $16.00
2016-05-20 Reiterated Rating Mizuho Buy $13.00
2016-05-03 Reiterated Rating Brean Capital Buy
2016-05-03 Reiterated Rating Cowen and Company Buy
2016-04-17 Reiterated Rating Cowen and Company Buy
2016-02-27 Reiterated Rating Brean Capital Buy $16.00
2016-01-27 Reiterated Rating Brean Capital Buy $16.00
2016-01-20 Reiterated Rating Mizuho Positive to Buy $13.00
2015-12-30 Reiterated Rating Oppenheimer Buy
2015-12-30 Reiterated Rating Oppenheimer Holdings Inc. Buy
2015-12-29 Reiterated Rating Mizuho Buy $16.00 to $13.00
2015-12-24 Reiterated Rating Oppenheimer Buy $15.00
2015-12-23 Lower Price Target Mizuho Buy $16.00 to $13.00
2015-10-27 Boost Price Target Oppenheimer Outperform $13.00 to $15.00
2015-10-23 Reiterated Rating Brean Capital Buy $16.00
2015-10-22 Reiterated Rating Mizuho Buy $16.00
2015-10-06 Reiterated Rating Brean Capital Buy $16.00
2015-09-22 Reiterated Rating Oppenheimer Outperform $13.00
2015-08-12 Reiterated Rating Mizuho Outperform $16.00
2015-08-12 Initiated Coverage Oppenheimer Outperform $13.00
2015-08-11 Reiterated Rating Brean Capital Buy $16.00
2015-08-11 Reiterated Rating Cantor Fitzgerald Buy $16.00
2015-06-15 Reiterated Rating Cantor Fitzgerald Buy $16.00
2015-05-13 Initiated Coverage Guggenheim Buy $15.00
2015-04-21 Boost Price Target Mizuho Buy $13.00 to $16.00
2015-02-27 Reiterated Rating Cantor Fitzgerald Buy $16.00
2015-02-26 Set Price Target Cantor Fitzgerald Buy $16.00
2014-12-19 Set Price Target Cantor Fitzgerald Buy $16.00
2014-12-19 Set Price Target Brean Capital Buy $16.00
2014-10-10 Initiated Coverage Oppenheimer Outperform $9.00 to $11.00
2014-09-24 Reiterated Rating Cantor Fitzgerald Buy
2014-09-08 Initiated Coverage Cantor Fitzgerald Buy $16.00
2014-07-08 Initiated Coverage Brean Capital Buy $16.00
2014-06-20 Lower Price Target Oppenheimer Outperform $10.00 to $8.50
2014-06-20 Reiterated Rating JPMorgan Chase & Co. Overweight $15.00 to $14.00
2014-05-02 Boost Price Target Mizuho $12.00 to $13.00
2014-05-01 Upgrade Cowen and Company Market Perform to Outperform
2014-05-01 Boost Price Target JPMorgan Chase & Co. $9.00 to $15.00
2013-11-08 Boost Price Target Brean Capital $14.00 to $16.00
2012-05-08 Initiated Oppenheimer Outperform $12
2016-05-26 Initiated Coverage Robert W. Baird Neutral $8.00
2016-05-20 Reiterated Rating Brean Capital Buy $16.00
2016-05-20 Reiterated Rating Mizuho Buy $13.00
2016-05-03 Reiterated Rating Brean Capital Buy
2016-05-03 Reiterated Rating Cowen and Company Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
CROCKER GARY L 2.81%  (2943961) MACK /
Mulroy Robert J. President and CEO 1.61%  (1683328) MACK /
Nash Sarah E 0.91%  (955296) BLKB / KNL / MACK /
PORTER MICHAEL E 0.80%  (839448) MACK / PTC / SMG /
Sinskey Anthony J 0.40%  (422543) MACK / MBLX /
Fehr Gordon J. 0.21%  (215143) MACK /
Dresser James van B. 0.16%  (168974) MACK /
Niyikiza Clet M. EVP of Development 0.14%  (141507) MACK /
Dineen John M. 0.10%  (100000) CTSH / MACK /
Schoeberl Birgit M. Head of Discovery 0.06%  (65657) MACK /
Lee Vivian S 0.06%  (65000) MACK / ZION /
Quigley James H. 0.05%  (56500) HES / MACK / WFC /
Stewart Edward J. SVP & Pres, Healthcare Sol 0.05%  (51385) MACK /
Nielsen Ulrik B. SVP and CSO 0.02%  (22681) MACK /
Sullivan William A. CFO and Treasurer 0.02%  (21596) AGTC / MACK /
McClements William M. SVP of Corporate Operations 0.01%  (14072) MACK /